Erin Kaltenbrun, Ph.D.
Director, Investments
Department: Emerging Company DevelopmentContact Information
About
Erin Kaltenbrun is a Director of Investments within the Emerging Company Development unit at NCBiotech. In this role, she sources, evaluates, and recommends early-stage life science companies for investment through NCBiotech’s loan programs and supports portfolio companies through mentorship during early growth and enhancing connections to follow-on financial support and strategic partnerships.
Erin brings 15+ years of experience in life science research, product development strategy, and technology commercialization to the role. Before joining NCBiotech, Erin oversaw the nondilutive funding portfolio for the immunotherapy-focused company NightHawk Biosciences (formerly Heat Biologics), successfully securing over $1M in funding support for discovery and preclinical programs, while contributing to new product planning and strategic oversight of R&D. As a consultant for Eva Garland Consulting, Erin worked with emerging companies to identify and secure nondilutive funding to support technology development and commercialization. Erin has taught SBIR/STTR seminars and workshops around the state and served as a mentor on various innovation initiatives including the NIH SBIR/STTR Application Assistance Program, the Kentucky Innovation Investment Program, and the University of Vermont iTREP Program. Erin began her career in industry at Charles River Laboratories, where she gained experience running IND-enabling PK and immunogenicity programs.
Erin received a Bachelor of Science from the University of Nevada, Reno and a Ph.D. in Molecular Biology from the University of North Carolina at Chapel Hill. She served as a Ruth L. Kirchstein Postdoctoral Fellow at Duke University Medical Center.